Reinhold E. Schmidt
Expertise in
15
conditions

Reinhold E. Schmidt

Carl Neuberg Str. 1, 
Hannover, NI, DE 
Expertise in
15
conditions
Carl Neuberg Str. 1, 
Hannover, NI, DE 
OverviewLocationsClinical Research

Overview

Reinhold Schmidt practices in Hannover, Germany. Mr. Schmidt is highly rated in 15 conditions, according to our data. His top areas of expertise are Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy, Dementia, Alzheimer's Disease, and Vascular Dementia.

His clinical research consists of co-authoring 618 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender
Male

Locations

Carl Neuberg Str. 1, Hannover, NI 30625, Germany
Other Locations
660 S. Euclid Ave, St. Louis, MO 63110
6020 Rutland Drive #14, Carmichael, CA 95608

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A 6-months Prospective, Multi-center, Double-blind, Placebo-controlled, Randomized, Adaptive-trial-design Study to Evaluate Safety, Tolerability and Exploratory Endpoints of Either Placebo or Two Different Oral Doses of LM11A-31-BHS in Patients With Mild to Moderate Probable Alzheimer's Disease
A 6-months Prospective, Multi-center, Double-blind, Placebo-controlled, Randomized, Adaptive-trial-design Study to Evaluate Safety, Tolerability and Exploratory Endpoints of Either Placebo or Two Different Oral Doses of LM11A-31-BHS in Patients With Mild to Moderate Probable Alzheimer's Disease
Enrollment Status: Completed
Publish Date: September 04, 2020
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A 24 Months Randomised, Placebo-controlled, Parallel Group, Double Blinded, Multi Centre, Phase 2 Study to Assess Safety and Efficacy of AADvac1 Applied to Patients With Mild Alzheimer's Disease
A 24 Months Randomised, Placebo-controlled, Parallel Group, Double Blinded, Multi Centre, Phase 2 Study to Assess Safety and Efficacy of AADvac1 Applied to Patients With Mild Alzheimer's Disease
Enrollment Status: Completed
Publish Date: November 14, 2019
Intervention Type: Drug, Biological
Study Phase: Phase 2
View 1 Less Clinical Trial

618 Total Publications

Signature White Matter Hyperintensity Locations Associated With Vascular Risk Factors Derived From 15 653 Individuals.
Signature White Matter Hyperintensity Locations Associated With Vascular Risk Factors Derived From 15 653 Individuals.
Journal: Stroke
Published: August 20, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Schmidt's expertise for a condition
ConditionClose
    View All 10 Advanced Conditions
    View All 96 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile